ES2179040T3 - Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b. - Google Patents

Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.

Info

Publication number
ES2179040T3
ES2179040T3 ES92906520T ES92906520T ES2179040T3 ES 2179040 T3 ES2179040 T3 ES 2179040T3 ES 92906520 T ES92906520 T ES 92906520T ES 92906520 T ES92906520 T ES 92906520T ES 2179040 T3 ES2179040 T3 ES 2179040T3
Authority
ES
Spain
Prior art keywords
hepatitis
treatment
thiacitidine
desoxi
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906520T
Other languages
English (en)
Inventor
Dennis C Liotta
Raymond F Schinazi
Woo-Baeg Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919104741A external-priority patent/GB9104741D0/en
Priority claimed from GB919109505A external-priority patent/GB9109505D0/en
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of ES2179040T3 publication Critical patent/ES2179040T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCUBRE EL USO DE UN ANALOGO DE 1,3 EOSIDO Y DERIVADOS FARMACEUTICAMENTE ACEPTABLES DE EL PARA EL TRATAMIENTO DE INFECCIONES VIRICAS DE HEPATITIS B. TAMBIEN SE PROVEEN FORMULACIONES FARMACEUTICAS.
ES92906520T 1991-03-06 1992-03-05 Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b. Expired - Lifetime ES2179040T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919104741A GB9104741D0 (en) 1991-03-06 1991-03-06 Therapeutic nucleosides
GB919109505A GB9109505D0 (en) 1991-05-02 1991-05-02 Therapeutic nucleosides

Publications (1)

Publication Number Publication Date
ES2179040T3 true ES2179040T3 (es) 2003-01-16

Family

ID=26298535

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01202860T Expired - Lifetime ES2286072T3 (es) 1991-03-06 1992-03-05 Sales de amidas de (-)cis 5 fluoro-2'-dedoxi-3'-tiacitidina utiles para el tratamiento de la hepatitis b.
ES92906520T Expired - Lifetime ES2179040T3 (es) 1991-03-06 1992-03-05 Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01202860T Expired - Lifetime ES2286072T3 (es) 1991-03-06 1992-03-05 Sales de amidas de (-)cis 5 fluoro-2'-dedoxi-3'-tiacitidina utiles para el tratamiento de la hepatitis b.

Country Status (21)

Country Link
EP (3) EP1808434A3 (es)
JP (5) JP3479068B2 (es)
KR (1) KR100270806B1 (es)
AT (2) ATE219366T1 (es)
AU (1) AU662130B2 (es)
CA (1) CA2105486C (es)
CZ (1) CZ282747B6 (es)
DE (2) DE69233693T2 (es)
DK (2) DK0574487T3 (es)
ES (2) ES2286072T3 (es)
HU (1) HUT64844A (es)
IE (1) IE920701A1 (es)
IL (1) IL101144A (es)
MX (1) MX9203213A (es)
NZ (1) NZ264621A (es)
PT (1) PT100198B (es)
RU (1) RU2116789C1 (es)
SK (1) SK279542B6 (es)
TW (1) TW201268B (es)
UA (1) UA54364C2 (es)
WO (1) WO1992015308A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2196004T3 (es) * 1989-02-08 2003-12-16 Iaf Biochem Int Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales.
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
CA2637774C (en) 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ATE346651T1 (de) 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
ATE267198T1 (de) * 1997-03-19 2004-06-15 Univ Emory Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
CN100387237C (zh) 1998-08-10 2008-05-14 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β-L-2'-脱氧-核苷
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
JP4249393B2 (ja) 1998-08-12 2009-04-02 トライアングル・ファーマシューティカルズ，インコーポレイテッド １，３−オキサチオランヌクレオチドの製造方法
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
RU2237479C2 (ru) * 1998-11-05 2004-10-10 Сантр Насьональ Де Ля Решерш Сьентифик Нуклеозиды, обладающие активностью против вируса гепатита в
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2002094844A2 (en) * 2001-05-18 2002-11-28 Rakesh Kumar Antiviral nucleosides
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
AU2003278816A1 (en) 2002-09-13 2004-04-30 Idenix (Cayman) Limited ss-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
PL377287A1 (pl) 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
US9320738B2 (en) * 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
WO2013004658A1 (en) * 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
WO1990014079A1 (en) 1989-05-15 1990-11-29 The United States Of America, Represented By The Secretary, United States Department Of Commerce Method of treatment of hepatitis
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides

Also Published As

Publication number Publication date
JP4891435B2 (ja) 2012-03-07
JP3987335B2 (ja) 2007-10-10
DE69232649T2 (de) 2002-11-28
ES2286072T3 (es) 2007-12-01
HU9302493D0 (en) 1993-11-29
CA2105486C (en) 2003-10-28
SK279542B6 (sk) 1998-12-02
EP1808434A2 (en) 2007-07-18
ATE219366T1 (de) 2002-07-15
UA54364C2 (uk) 2003-03-17
JP2002220388A (ja) 2002-08-09
WO1992015308A1 (en) 1992-09-17
DK1142891T3 (da) 2007-08-27
AU662130B2 (en) 1995-08-24
CZ282747B6 (cs) 1997-09-17
DE69233693T2 (de) 2008-01-24
PT100198A (pt) 1993-05-31
TW201268B (es) 1993-03-01
EP1142891B1 (en) 2007-05-02
JPH06505725A (ja) 1994-06-30
IE920701A1 (en) 1992-09-09
KR100270806B1 (ko) 2000-11-01
EP1142891A1 (en) 2001-10-10
JP2010013466A (ja) 2010-01-21
DK0574487T3 (da) 2002-10-14
CA2105486A1 (en) 1992-09-07
MX9203213A (es) 1992-07-01
PT100198B (pt) 2000-03-31
NZ264621A (en) 1997-09-22
ATE361293T1 (de) 2007-05-15
JP2011102308A (ja) 2011-05-26
SK95093A3 (en) 1994-04-06
HUT64844A (en) 1994-03-28
JP2007246536A (ja) 2007-09-27
IL101144A (en) 1996-09-12
JP3479068B2 (ja) 2003-12-15
DE69232649D1 (de) 2002-07-25
IL101144A0 (en) 1992-11-15
EP0574487A1 (en) 1993-12-22
DE69233693D1 (de) 2007-06-14
AU1367692A (en) 1992-10-06
CZ183593A3 (en) 1994-04-13
EP1808434A3 (en) 2008-04-02
RU2116789C1 (ru) 1998-08-10
JP4399478B2 (ja) 2010-01-13
EP0574487B1 (en) 2002-06-19
IE20040402A1 (en) 2007-10-17

Similar Documents

Publication Publication Date Title
EP1808434A3 (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine fo the treatment of hepatitis B
ES2083668T5 (es) Combinaciones antiviricas que contienen analogos de nucleosido.
ATE185483T1 (de) Antivirale nucleosidkombination
MX9205046A (es) 1h-imidazo-(4,5-c)quinolin-4-aminas 1-substituidas
ES2186667T3 (es) Analogos de nucleosidos de 1,3-oxatiolano.
SE8804629D0 (sv) New therapeutically active compounds
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
MY107843A (en) Anti-viral compounds.
NL300136I2 (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
MX9200361A (es) Nuevo uso del antagonista de adenosina.
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
MY137298A (en) Therapeutic nucleosides
TR199900013T2 (xx) Yeni bile�ikler.
SE9604752D0 (sv) Formulation and use
BR9106372A (pt) Derivados 1,5-benzotiazepinona,suas preparacoes e uso farmaceutico
SE9602262D0 (sv) New use of derivatives of cystine
ES2150034T3 (es) Empleo de las 2-aminotetralinas substituidas en 6,7 para la preparacion de composiciones farmaceuticas de utilidad para el tratamiento del choque septico, y composiciones farmaceuticas antipireticas y antiinflamatorias.
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
MY113560A (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b
ES2169116T3 (es) Uso de los derivados de 2-amino purina en el tratamiento y profilaxis del virus 6 del herpes humano.
ITRM920930A1 (it) Impiego del glutatione per la preparazione di composizioni farmaceutiche ad attivita' antivirale.
MX9203485A (es) Derivados de tieno sulfonamida, composiciones farmaceuticas y uso.
ITRM920173A1 (it) Composizione a base di ibuprofen per uso orale.